A Phase 1, Within Cohort, Randomized, Double Blind, Third-party Open, Placebo-controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06826647 In Healthy Subjects And Subjects With Plaque Psoriasis

Trial Profile

A Phase 1, Within Cohort, Randomized, Double Blind, Third-party Open, Placebo-controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06826647 In Healthy Subjects And Subjects With Plaque Psoriasis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs PF 06826647 (Primary) ; PF 06826647 (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer
  • Most Recent Events

    • 11 Dec 2017 Planned number of patients changed from 90 to 114.
    • 11 Dec 2017 Planned End Date changed from 24 Jul 2018 to 25 Aug 2018.
    • 11 Dec 2017 Planned primary completion date changed from 24 Jul 2018 to 25 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top